Find Funding Opportunities

The purpose of this funding opportunity announcement (FOA) is to 1) support hypothesis driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for Parkinsons Disease (PD) and 2) support the collection of clinical data and new biological specimens that will be used for biomarker exploratory efforts under the NINDS Parkinsons Disease Biomarkers Program (PDBP). Applications may include both of these goals if justified. Studies using either existing or new cohorts may be appropriate. For all applications, applicants must describe statistical justification for the number of subjects/samples proposed and a clear scientific rationale for the range and types of subjects/samples to be collected. Broad sharing of data and biological specimens with academic, industry and government researchers is a critical feature of the PDBP generally and of this FOA specifically, in order to provide valuable research resources for the scientific community to advance Parkinsons Disease research in an efficient and effective manner (consistent with applicable laws, regulations, and policies); therefore, all subjects in any proposed study must be properly consented to allow appropriate sample and data distribution to researchers in academics and industry.

The purpose of this funding opportunity announcement (FOA) is to stimulate innovation and development of technologies and reagents that will accelerate the discovery of biological biomarkers for Parkinsons disease (PD). It is expected that the NINDS Parkinsons disease biomarkers program (PDBP) will consolidate, integrate and enhance NINDS-funded PD biomarkers research projects. This FOA will foster research into biospecimen preparation methodologies, quantitative analyte analysis, reagent and assay development, and data analysis methods needed for PD biomarkers progress to occur. Utilization of extant specimens and data for novel discovery projects is permitted under this FOA, as long as consent enables deposition of all data into the PDBP Data Management Resource (DMR).

On February 7, 2012, Secretary of Health and Human Services Kathleen Sebelius announced that $50 million would be directed immediately to boost Alzheimers research in FY2012 in response to President Obama signing the National Alzheimer's Project Act. This increased funding will likely cover a range of projects, including basic science on the biology and genetics of Alzheimers disease as well as translational and clinical research in development and testing of therapies. The purpose of this funding opportunity announcement is to solicit Small Business Innovation Research (SBIR) applications from eligible small business concerns in the area of Alzheimer's disease.

On February 7, 2012, Secretary of Health and Human Services Kathleen Sebelius announced that $50 million would be directed immediately to boost Alzheimers research in FY2012 in response to President Obama signing the National Alzheimer's Project Act. This increased funding will likely cover a range of projects, including basic science on the biology and genetics of Alzheimers disease as well as translational and clinical research in development and testing of therapies. The purpose of this funding opportunity announcement is to solicit Small Business Technology Transfer Research (STTR) applications from eligible small business concerns in the area of Alzheimer's disease.

The National Institutes of Health (NIH) announces a unique opportunity for investigators working with small molecule compounds to gain access to a robust virtual pharma network to discover neurotherapeutic drugs. Successful applicants to this FOA will become collaborative participants in this network, receiving both funding and no-cost access to contracted drug discovery services that are not typically available to the academic research community. Funding will be provided through a U01 cooperative agreement mechanism to conduct biological testing of compound analogs in disease assays and models in the investigators laboratory. No-cost drug discovery services will also be provided, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. Researchers in possession of disease assays and small molecule compounds that show promise for treating nervous system and psychiatric disorders, but that are not yet suitable for clinical testing, are strongly encouraged to apply.

The National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Allergy and Infectious Disease (NIAID) invite research grant applications to address the problem of HIV-1 persistence focused solely on the central nervous system (CNS) of HIV-infected persons treated with Highly Active Anti-Retroviral Therapy (HAART). This Funding Opportunity Announcement (FOA) will support innovative research in five areas: (1) basic research to identify and characterize CNS-based cellular reservoirs of HIV-1 for individuals on HAART; (2) basic research to determine the mechanisms involved in the temporal establishment, maintenance, and resurgence of CNS-based HIV-1 reservoirs in relationship to the effects and timing of HAART, viral expression, and viral evolution within the brain; (3) development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART; (4) drug screening of potential agents which traverse the blood-brain barrier and eliminate latent or other sources of residual virus in the CNS; and (5) design of therapeutic strategies aimed at eradication of HIV-1 from the CNS. Applications ranging from basic to translational research in domestic and international settings are of interest. Multidisciplinary research teams are encouraged but not required.

The National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS) invite novel research grant applications to address the problem of HIV-1 persistence focused solely on the central nervous system (CNS) of HIV-infected persons treated with Highly Active Anti-Retroviral Therapy (HAART). This Funding Opportunity Announcement (FOA) will support highly innovative research in five areas: (1) basic research to identify and characterize CNS-based cellular reservoirs of HIV-1 for individuals on HAART; (2) basic research to determine the mechanisms involved in the temporal establishment, maintenance, and resurgence of CNS-based HIV-1 reservoirs in relationship to the effects and timing of HAART, viral expression, and viral evolution within the brain; (3) development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART; (4) drug screening of potential agents which traverse the blood-brain barrier and eliminate latent or other sources of residual virus in the CNS; and (5) design of therapeutic strategies aimed at eradication of HIV-1 from the CNS. Applications ranging from basic to translational research in domestic and international settings are of interest. Multidisciplinary research teams are encouraged but not required.

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.A list of those web sites is available at http://grants.nih.gov/grants/guide/admin_supp/index.htm.

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for ancillary studies that will further our understanding of the unique clinical and biomarker signatures of premanifest or prodromal Huntington's disease (HD) through coordination with the NINDS-funded Neurobiological Predictors of Huntington's Disease (PREDICT-HD) study. The PREDICT-HD study is an international 32-site observational study of persons at-risk for HD, and includes clinical and biospecimen resources from 800 premanifest HD participants and 200 healthy control subjects. Extensive clinical data including UHDRS motor examination, cognitive and neuropsychiatric assessments, and structural MRI imaging have been collected over a ten-year time frame, with a subset of these data accessible through the dbGaP website http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs….

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2012-2 SBIR/STTR Program Descriptions and Research Topics for NIH.)